

# Åyvind S Bruland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7961929/publications.pdf>

Version: 2024-02-01

125  
papers

5,638  
citations

134610

34  
h-index

93651

72  
g-index

127  
all docs

127  
docs citations

127  
times ranked

5990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors. <i>Acta Radiologica</i> , 2022, 63, 995-1004.	0.5	4
2	Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours. <i>Anticancer Research</i> , 2022, 42, 955-963.	0.5	2
3	Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand <sup>212</sup> Pb-NG001. <i>Cancers</i> , 2022, 14, 2784.	1.7	7
4	Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study. <i>Acta Oncologica</i> , 2022, 61, 793-800.	0.8	1
5	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. <i>JAMA Oncology</i> , 2021, 7, e205865.	3.4	45
6	Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 779.	1.7	45
7	Radon-220 diffusion from <sup>224</sup> Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use. <i>PLoS ONE</i> , 2021, 16, e0248133.	1.1	7
8	Evaluation of the PSMA-Binding Ligand <sup>212</sup> Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4815.	1.8	19
9	Calcium Carbonate Microparticles as Carriers of <sup>224</sup> Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer. <i>Current Radiopharmaceuticals</i> , 2021, 14, 145-153.	0.3	11
10	Does the Lightning Process Training Programme Reduce Chronic Fatigue in Adolescent and Young Adult Cancer Survivors? A Mixed-Methods Pilot Study. <i>Cancers</i> , 2021, 13, 4076.	1.7	5
11	Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma. <i>Acta Veterinaria Scandinavica</i> , 2021, 63, 41.	0.5	2
12	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5334.	1.0	2
13	Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [ <sup>212</sup> Pb]Pb-NG001 for prostate cancer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 129-143.	0.5	34
14	Calibration of sodium iodide detectors and reentrant ionization chambers for <sup>212</sup> Pb activity in different geometries by HPGc activity determined samples. <i>Applied Radiation and Isotopes</i> , 2020, 166, 109362.	0.7	10
15	Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study. <i>Clinical Sarcoma Research</i> , 2020, 10, 22.	2.3	3
16	In situ Generated <sup>212</sup> Pb-PSMA Ligand in a <sup>224</sup> Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells. <i>Current Radiopharmaceuticals</i> , 2020, 13, 130-141.	0.3	16
17	Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. <i>Clinical Sarcoma Research</i> , 2020, 10, 2.	2.3	2
18	Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas – A nationwide population-based study. <i>Journal of Bone Oncology</i> , 2019, 14, 100207.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years. <i>Journal of Bone Oncology</i> , 2019, 14, 100216.	1.0	10
20	Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. <i>Clinical Sarcoma Research</i> , 2019, 9, 6.	2.3	10
21	Prognostic Impact of Proximal Versus Distal Localization in Extremity Long Bone Osteosarcomas. <i>Anticancer Research</i> , 2019, 39, 2459-2466.	0.5	5
22	Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	2
23	Therapeutic Effect of $\beta$ -Emitting $^{224}\text{Ra}$ -Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer. <i>Translational Oncology</i> , 2018, 11, 259-267.	1.7	23
24	Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1133-1139.	0.7	40
25	$^{224}\text{Ra}$ labeling of calcium carbonate microparticles for internal $\beta$ -therapy: Preparation, stability, and biodistribution in mice. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 472-486.	0.5	39
26	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018, 73, 427-435.	0.9	84
27	Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. <i>Journal of Surgical Oncology</i> , 2018, 118, 246-247.	0.8	2
28	Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors – A Scandinavian Sarcoma Group study (SSG XX). <i>European Journal of Cancer</i> , 2018, 99, 78-85.	1.3	26
29	Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 328-331.	0.9	4
30	Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. <i>Acta Oncologica</i> , 2017, 56, 1317-1323.	0.8	15
31	Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. <i>Neurosurgical Review</i> , 2017, 40, 449-460.	1.2	16
32	Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. <i>Clinical Sarcoma Research</i> , 2016, 6, 21.	2.3	7
33	Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene. <i>PLoS ONE</i> , 2016, 11, e0163859.	1.1	13
34	Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. <i>PLoS ONE</i> , 2016, 11, e0165382.	1.1	21
35	Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the "Classical" Patient. <i>Sarcoma</i> , 2015, 2015, 1-14.	0.7	36
36	Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009. <i>Sarcoma</i> , 2015, 2015, 1-9.	0.7	42

#	ARTICLE	IF	CITATIONS
37	Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2015, 54, 25-33.	0.8	100
38	Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females. <i>Scandinavian Journal of Public Health</i> , 2015, 43, 324-330.	1.2	7
39	Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas. <i>Anticancer Research</i> , 2015, 35, 1171-80.	0.5	1
40	Extraskelletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature. <i>Anticancer Research</i> , 2015, 35, 2129-40.	0.5	18
41	Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?. <i>Anticancer Research</i> , 2015, 35, 5759-65.	0.5	4
42	Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study. <i>Anticancer Research</i> , 2015, 35, 6081-90.	0.5	13
43	Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma – a predictor of outcome?. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2014, 53, 1180-1187.	0.8	12
44	Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2014, 53, 143-148.	0.8	11
45	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 738-746.	5.1	433
46	Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI. <i>Journal of Bone Oncology</i> , 2014, 3, 5-9.	1.0	6
47	<sup>177</sup> Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice. <i>PLoS ONE</i> , 2014, 9, e103070.	1.1	22
48	Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. <i>Anticancer Research</i> , 2014, 34, 3263-9.	0.5	6
49	Incidence and mortality of second sarcomas – A population-based study. <i>European Journal of Cancer</i> , 2013, 49, 3292-3302.	1.3	8
50	Patterns of Local Recurrence and Dose Fractionation of Adjuvant Radiation Therapy in 462 Patients With Soft Tissue Sarcoma of Extremity and Trunk Wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 949-955.	0.4	14
51	Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223. <i>Medical Radiology</i> , 2013, , 447-457.	0.0	1
52	Targeted radio-nuclide therapy of skeletal metastases. <i>Cancer Treatment Reviews</i> , 2013, 39, 18-26.	3.4	50
53	Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 20-26.	0.9	98
54	Intermittent and continuous imatinib in a human GIST xenograft model carrying <i>KIT</i> exon 17 resistance mutation D816H. <i>Acta Oncol</i> <sup>3</sup> <i>gica</i> , 2013, 52, 776-782.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Biologic targets identified from dynamic <sup>18</sup> F-FDG-PET and implications for image-guided therapy. <i>Acta Oncologica</i> , 2013, 52, 1378-1383.	0.8	10
56	Quantitative dynamic <sup>18</sup> F-FDG-PET and tracer kinetic analysis of soft tissue sarcomas. <i>Acta Oncologica</i> , 2013, 52, 1160-1167.	0.8	16
57	The Clinical Impact of Mean Vessel Size and Solidity in Breast Carcinoma Patients. <i>PLoS ONE</i> , 2013, 8, e75954.	1.1	10
58	Superficial-spreading and nodular melanomas in Norway. <i>Melanoma Research</i> , 2012, 22, 460-465.	0.6	17
59	Global Gene Expression Profiling of Human Osteosarcomas Reveals Metastasis-Associated Chemokine Pattern. <i>Sarcoma</i> , 2012, 2012, 1-12.	0.7	33
60	Preclinical evaluation of <sup>227</sup> Th-labeled and <sup>177</sup> Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. <i>Nuclear Medicine Communications</i> , 2012, 33, 838-847.	0.5	28
61	Radiotherapy or surgery for spine metastases?. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011, 82, 365-371.	1.2	15
62	Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011, 82, 211-216.	1.2	53
63	Five-Year Results From a Scandinavian Sarcoma Group Study (SSG XIII) of Adjuvant Chemotherapy Combined With Accelerated Radiotherapy in High-Risk Soft Tissue Sarcoma of Extremities and Trunk Wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1359-1366.	0.4	20
64	Experimental $\alpha$ -particle radioimmunotherapy of breast cancer using <sup>227</sup> Th-labeled p-benzyl-DOTA-trastuzumab. <i>EJNMMI Research</i> , 2011, 1, 18.	1.1	47
65	Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT. <i>Molecular Imaging and Biology</i> , 2011, 13, 1234-1240.	1.3	12
66	DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. <i>Acta Oncologica</i> , 2011, 50, 148-150.	0.8	15
67	Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates. <i>Current Radiopharmaceuticals</i> , 2011, 4, 321-328.	0.3	21
68	Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,. <i>Blood</i> , 2011, 118, 3732-3732.	0.6	1
69	Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966–2007. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2010, 101, 174-178.	1.7	32
70	Vitamin D Status, Solar Radiation and Cancer Prognosis. , 2010, , 765-775.		0
71	Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience. <i>Acta Oncologica</i> , 2009, 48, 1165-1172.	0.8	19
72	Photochemical Internalization of Bleomycin Before External-Beam Radiotherapy Improves Locoregional Control in a Human Sarcoma Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 878-885.	0.4	13

#	ARTICLE	IF	CITATIONS
73	DCEMRI of spontaneous canine tumors during fractionated radiotherapy: A pharmacokinetic analysis. <i>Radiotherapy and Oncology</i> , 2009, 93, 618-624.	0.3	10
74	Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience. <i>Cancer Treatment and Research</i> , 2009, 152, 309-318.	0.2	18
75	Bone Marrow Micrometastases Studied by an Immunomagnetic Isolation Procedure in Extremity Localized Non-metastatic Osteosarcoma Patients. <i>Cancer Treatment and Research</i> , 2009, 152, 509-515.	0.2	13
76	Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. <i>Prostate</i> , 2008, 68, 1607-1614.	1.2	4
77	Sun beds and cod liver oil as vitamin D sources. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2008, 91, 125-131.	1.7	43
78	Radiotherapy to Improve Local Control Regardless of Surgical Margin and Malignancy Grade in Extremity and Trunk Wall Soft Tissue Sarcoma: A Scandinavian Sarcoma Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1196-1203.	0.4	129
79	Relative Biologic Effects of Low-Dose-Rate $\beta^{\pm}$ -Emitting $^{227}\text{Th}$ -Rituximab and $\beta^2$ -Emitting $^{90}\text{Y}$ -Tiuxetan-Ibritumomab Versus External Beam X-Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 186-192.	0.4	36
80	Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation. <i>Acta Oncologica</i> , 2008, 47, 248-254.	0.8	17
81	DCEMRI monitoring of canine tumors during fractionated radiotherapy. <i>Acta Oncologica</i> , 2008, 47, 1249-1256.	0.8	12
82	Targeted High-LET Therapy of Bone Metastases. , 2008, , 181-194.		3
83	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. <i>Physics in Medicine and Biology</i> , 2007, 52, 499-513.	1.6	77
84	Some musculo-skeletal sequelae in cancer survivors. <i>Acta Oncologica</i> , 2007, 46, 490-496.	0.8	24
85	Targeted cancer therapy with a novel low-dose rate $\beta^{\pm}$ -emitting radioimmunoconjugate. <i>Blood</i> , 2007, 110, 2049-2056.	0.6	80
86	Proton therapy – A systematic review of clinical effectiveness. <i>Radiotherapy and Oncology</i> , 2007, 83, 123-132.	0.3	168
87	Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. <i>Lancet Oncology</i> , The, 2007, 8, 587-594.	5.1	461
88	Preparation of $^{227}\text{Th}$ -Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 431-437.	0.7	45
89	Seasonal and geographical variations in lung cancer prognosis in Norway. <i>Lung Cancer</i> , 2007, 55, 263-270.	0.9	96
90	Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. <i>International Journal of Cancer</i> , 2007, 120, 1603-1609.	2.3	50

#	ARTICLE	IF	CITATIONS
91	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1496-1504.	0.4	70
92	10-Year Survival and Quality of Life in Patients With High-Risk PNO Prostate Cancer Following Definitive Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1074-1083.	0.4	11
93	Initial evaluation of <sup>227</sup> Th-p-benzyl-DOTA-rituximab for low-dose rate $\alpha$ -particle radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 2006, 33, 271-279.	0.3	55
94	Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience. <i>Acta Oncologica</i> , 2006, 45, 38-46.	0.8	30
95	High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the $\alpha$ -Emitter <sup>223</sup> Ra: Adjuvant or Alternative to Conventional Modalities?. <i>Clinical Cancer Research</i> , 2006, 12, 6250s-6257s.	3.2	303
96	Adapting radiotherapy to hypoxic tumours. <i>Physics in Medicine and Biology</i> , 2006, 51, 4903-4921.	1.6	70
97	TP-3 Immunotoxins Improve Antitumor Activity in Mice with Osteosarcoma. <i>Clinical Orthopaedics and Related Research</i> , 2005, 430, 142-148.	0.7	10
98	Primary osteosarcoma of the breast. <i>Acta Oncologica</i> , 2005, 44, 767-770.	0.8	15
99	First Clinical Experience with $\alpha$ -Emitting Radium-223 in the Treatment of Skeletal Metastases. <i>Clinical Cancer Research</i> , 2005, 11, 4451-4459.	3.2	421
100	Telemedicine in radiotherapy: a study exploring remote treatment planning, supervision and economics. <i>Journal of Telemedicine and Telecare</i> , 2005, 11, 245-250.	1.4	34
101	Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts. <i>Cancer Research</i> , 2004, 64, 4768-4773.	0.4	208
102	Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts. <i>Cancer Research</i> , 2004, 64, 547-553.	0.4	143
103	Targeting of osseous sites with alpha-emitting <sup>223</sup> Ra: comparison with the beta-emitter <sup>89</sup> Sr in mice. <i>Journal of Nuclear Medicine</i> , 2003, 44, 252-9.	2.8	171
104	Significant antitumor effect from bone-seeking, alpha-particle-emitting ( <sup>223</sup> Ra) demonstrated in an experimental skeletal metastases model. <i>Cancer Research</i> , 2002, 62, 3120-5.	0.4	220
105	Synthesis, purification and biodistribution of <sup>205</sup> Bi-DOTMP, visualizing bone deposition patterns with autoradiography. <i>Nuclear Medicine and Biology</i> , 2001, 28, 425-433.	0.3	10
106	Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A. <i>Journal of Immunotherapy</i> , 2001, 24, 144-150.	1.2	14
107	Telemedicine in radiotherapy treatment planning: requirements and applications. <i>Radiotherapy and Oncology</i> , 2000, 54, 255-259.	0.3	48
108	Two Human Osteoblast-like Osteosarcoma Cell Lines Show Distinct Expression and Differential Regulation of Parathyroid Hormone-Related Protein. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 904-914.	3.1	4

#	ARTICLE	IF	CITATIONS
109	Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 411-418.	2.0	6
110	Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of <sup>211</sup> At and <sup>125</sup> I-labeled amidobisphosphonates in mice. <i>Nuclear Medicine and Biology</i> , 1999, 26, 791-794.	0.3	16
111	Preliminary evaluation of a new radiolabelled biphosphonate. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998, 41, 823-830.	0.5	3
112	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1998, 4, 141-153.	2.4	19
113	Radiotherapy in Scandinavia. <i>Acta Oncologica</i> , 1998, 37, 553-560.	0.8	4
114	Targeted Radiotherapy of Osteosarcoma Using <sup>153</sup> Sm-Edtmp: A new promising approach. <i>Acta Oncologica</i> , 1996, 35, 381-384.	0.8	78
115	Abundant Tyrosine Residues in the Antigen Binding Site in Anti-Osteosarcoma Monoclonal Antibodies Tp-1 and Tp-3: Application to radiolabeling. <i>Acta Oncologica</i> , 1996, 35, 297-301.	0.8	16
116	Extremity and Non-Extremity High-Grade Osteosarcoma: The Norwegian Radium Hospital experience during the modern chemotherapy era. <i>Acta Oncologica</i> , 1996, 35, 129-134.	0.8	29
117	Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: Evidence for the involvement of Gi2 in cell proliferation. <i>Journal of Cellular Biochemistry</i> , 1996, 60, 95-106.	1.2	4
118	Cancer Therapy With Radiolabeled Antibodies An Overview. <i>Acta Oncologica</i> , 1995, 34, 1085-1094.	0.8	9
119	Radiolysis of radioimmunoconjugates. Reduction in antigen-binding ability by $\beta$ -particle radiation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1995, 36, 1009-1018.	0.5	10
120	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. <i>Nuclear Medicine and Biology</i> , 1995, 22, 765-771.	0.3	21
121	$\beta$ -Particle Radiotherapy with <sup>211</sup> At-Labeled Monodisperse Polymer Particles, <sup>211</sup> At-Labeled IgG Proteins, and Free <sup>211</sup> At in a Murine Intraperitoneal Tumor Model. <i>Gynecologic Oncology</i> , 1995, 57, 9-15.	0.6	429
122	<sup>212</sup> Pb/ <sup>212</sup> Bi-EDTMP - synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994, 34, 717-734.	0.5	21
123	Preparation and quality control of <sup>211</sup> At-labelled and <sup>125</sup> I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994, 34, 773-785.	0.5	14
124	Inactivation of Human Osteosarcoma Cells In Vitro by <sup>211</sup> At-TP-3 Monoclonal Antibody: Comparison with Astatine- <sup>211</sup> At-Labeled Bovine Serum Albumin, Free Astatine- <sup>211</sup> At and External-Beam X Rays. <i>Radiation Research</i> , 1994, 139, 178.	0.7	36
125	Chapter 86. Radiotherapy of Skeletal Metastases. , 0, , 404-407.		1